NCT01925859已完成1 期
Pharmacokinetics Study to Measure Plasma Concentrations of Dexamethasone Following EryDex (Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes) Infusion in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Pharmacokinetic comparison of two different doses of EryDex in two independent groups
研究概览
简要总结
To compare the pharmacokinetic properties of two different doses of EryDex (dexamethasone sodium phosphate encapsulated in erythrocytes) given as a single infusion in healthy volunteers, based on plasma concentrations of dexamethasone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ages 18-55 years, inclusive.
- •If female, the subject is not pregnant or lactating, and has negative serum pregnancy tests at Screening and Baseline (check-in).
- •If female of childbearing potential*, the subject agrees not to donate ova and to use one of the following methods of contraception from the time of signing the informed consent until 2 months after infusion.
- •Cap or diaphragm with spermicidal cream or jelly + male condom and spermicide.
- •Hormonal contraceptives (oral, implant, injection or patch) + male condom and spermicide.
- •Intrauterine devices + male condom or spermicide.
- •Vaginal ring + male condom and spermicide.
- •Non-childbearing potential is defined as surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation), hysterectomy at least 3 months before the start of the study, or postmenopausal (defined as continuous amenorrhea for at least 2 years).
- •If male, the subject agrees to not donate sperm and to use barrier contraception (e.g., condom with spermicidal cream or jelly) from the time of signing the informed consent until 2 months after infusion.
- •Physically and mentally healthy, as confirmed by medical history, physical examination, vital signs, clinical laboratory tests, and ECG.
- •The subject has a body weight of at least 45 kg and a body mass index of ≤
- •Written informed consent to participate was obtained from the subject.
- •Ability to understand the aims of the trial and comply with the study procedures.
排除标准
- •Females that are of childbearing potential, pregnant, or are breast-feeding. Women of childbearing potential using two forms of birth control (e.g. barrier and hormonal) will be eligible.
- •Loss/removal of 500 mL or more of blood within the past 4 weeks.
- •A disability that may prevent the subject from completing all study requirements.
- •Noncompliance with the study requirements. Medical History
- •Current or previous neoplastic disease.
- •History of any impairment of the immunological system.
- •History of drug or alcohol abuse (within past 5 years).
- •A current diagnosis of severe or unstable cardiovascular disease;
- •Any history or current evidence of a cardiac illness as determined by the investigator;
- •History or current diagnosis of a psychiatric illness (DSM-IV-TR Axis I diagnosis) or neurodegenerative disorder.
- •Smoker; currently or at any time in the last 6 months.
- •Hemoglobinopathy or G6PD deficiency.
- •History of recurrent or chronic infections, including Staphylococcus or methicillin-resistant Staphylococcus aureus (MRSA).
- •History of positive tuberculosis skin test (PPD test). Current Medical Status
- •Have any other significant disease or condition that in the Investigator's opinion would put the subject at risk for participating in the trial.
- •Vital signs outside the following ranges:
- •Systolic blood pressure <90 or >140 mmHg
- •Diastolic blood pressure <50 or >90 mmHg
- •Pulse <50 or >90 bpm. Patients with pulse rates <50 that are otherwise healthy will be eligible for the trial if approved by the Sponsor.
- •Any clinically significant ECG abnormality, including a disorder of rate, rhythm, or conduction, or other morphological changes.
- •Any clinically significant abnormality on standard laboratory examinations (hematology, biochemistry, urinalysis), as determined by the Investigator, in consultation with the Sponsor.
- •History of hepatitis B and/or C, and/or positive serology results, which indicate the presence of hepatitis B and/or C (Hepatitis B surface antigen and/or antibody to Hepatitis C).
- •Positive results from the HIV serology.
- •Positive results of the drug and alcohol tests at screening and/or check-in at the unit. Alcohol intake should be limited to 2 drinks per day during the 2 weeks prior to dosing; alcohol consumption will be prohibited from the time o
- •Clinically significant abnormal serum cortisol levels (below normal range or >1.5x ULN) at screening.
- •Prior/Concomitant Medication
- •Any previous steroid consumption within 4 weeks before Baseline.
- •Chronic condition or prior allergic reaction representing a contraindication to the use of steroid drugs.
- •Have participated in any other trial with an investigational drug and received a dose within 30 days or 10 half-lives (whichever is greater) from the start of the Screening Period.
- •Requirement for any prescription or over-the-counter (OTC) medication, other than hormonal birth control or occasional use of acetaminophen, that cannot be discontinued during screening, at least one week before Baseline, and throughout the 42-day study period.
- •f admittance on Day -1 through to the final safety evaluations on Day
- •A drug or treatment known to cause major organ system toxicity during the past year.
- •Caffeine-containing products in excess of the equivalent of 2 cups of coffee per day during the 2 weeks prior to dosing and through to the final safety evaluations on Day 42.
研究组 & 干预措施
EryDex System
Experimental
erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)
干预措施: EryDex (dexamethasone sodium phosphate encapsulated erythrocytes) (Drug)
结局指标
主要结局
Pharmacokinetic comparison of two different doses of EryDex in two independent groups
时间窗: 42 days after infusion
• To compare the pharmacokinetic (PK) properties of 2 different doses of EryDex (dexamethasone sodium phosphate encapsulated in erythrocytes) given as a single infusion in healthy volunteers, based on plasma concentrations of dexamethasone.
次要结局
- Evaluation of safety and tolerability of a single infusion of EryDex administered in two different doses in healthy volunteers(84 days after infusion)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Pharmacokinetics of Aqueous DexamethasonePharmacokineticsAqueous DexamethasoneInflammatory Cytokine ResponseNCT04667507Frank A. Bucci, Jr., M.D.102
已完成
1 期
A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT03215498Novo Nordisk A/S58
尚未招募
3 期
To compare the efficacy of dexamethasone and dexmedetomidine in post operative sore throat in adult patients undergoing laproscopic cholecystectomy .CTRI/2024/03/064770Jawaharlal Nehru Medical College and hospital
已完成
不适用
The measurement of dexmedetomidine for sedation in intensive care patientsIntensive care patientsJPRN-UMIN000009115agoya City University Graduate School of Medical Sciences50
终止
2 期
Iontophoresis With Dexamethasone and Physical Therapy to Treat Apophysitis of the Knee in PediatricsJuvenile ApophysitisNCT03606980Children's Health System, Inc.45